Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
← CataloguePlate VI of XXX
VIPlate VIReviewed 2026-04-25

Epitalon

Tetrapeptide bioregulator

also known as Epithalon, Epithalamin synthetic, Ala-Glu-Asp-Gly

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed at the Saint Petersburg Institute of Bioregulation and Gerontology as the active analog of epithalamin, a natural pineal extract. Khavinson et al. demonstrated telomerase-activating and telomere-elongating activity in human somatic cells. Long-term safety + efficacy data are dominated by Russian-language literature; Western RCTs are sparse. Frequently used anecdotally for longevity and sleep regulation.

§ I

At a glance

Per cycle dose
5–10 mg
Mechanistic
Human
Half-life (est)
Hours
Route

SQ or IM · Abdomen · Daily for 10–20 days

§ II

Mechanism

Primary target — Telomerase activity (proposed); pineal melatonin axis modulation [khavinson-2003].

Pathway — Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatonin [khavinson-2003].

Downstream effect — Telomere elongation, improved sleep architecture, reported lifespan extension in aged mice [khavinson-2003].

Origin — Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract) [khavinson-2003].

§ III

Dosage

Protocols described in the cited literature; not medical advice.

ParameterValue
Standard dose5–10 mg / day for 10–20 days, 1–2× per year [khavinson-2003]Anecdotal community protocol. Russian clinical literature uses similar cycling.
FrequencyOnce daily during a cycle
Lower / starter dose2.5 mg / day
Evidence basisIn-vitro telomerase + Russian clinical trials [khavinson-2003]
Duration10–20 day cycles, 1–2× per year
ReconstitutionBacteriostatic water
TimingPre-sleep preferred (pineal alignment)
Half-lifeHours (estimated)
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to Epitalon's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
0.050mL
5.0 units on a U-100 insulin syringe
Concentration
5000
mcg per mL
Doses per vial
40
at this dose
§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Injection site reactionmild
Mild irritation
Sleep architecturemild
Improved subjective sleep quality (anecdotal)
Cancer risksevere
Theoretical via telomerase activation in pre-malignant cells
Long-term safetymoderate
Limited Western RCT data
Pregnancy / OBsevere
Avoid
Antibody formationmild
Not reported
Absolute contraindications
  • Pregnancy / breastfeeding
  • Active malignancy or pre-malignant state
Relative contraindications
  • Family history of cancer
§ VI

Administration

  1. 01
    Reconstitution

    Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

  2. 02
    Injection site

    SQ — abdomen preferred. Rotate sites.

  3. 03
    Timing

    Pre-sleep preferred to align with pineal axis.

  4. 04
    Storage

    Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

  5. 05
    Needle

    29–31G, 4–8 mm insulin syringe.

Appendix

Sources

22%

of 37 rendered claims carry a resolvable citation.

  1. [khavinson-2003]
    Khavinson 2003Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
    Bull Exp Biol Med, 2003
Plate composed 2026-04-25 · maturity draft · schema v1 · Contributors: peptidesdb-core · 29 fields uncited — open contributions